Given our research findings that SGLT2 inhibitors could reduce uridine levels, and considering that uridine has a positive association with prostate cancer, we hypothesize that the anti-cancer ability of SGLT2 inhibitors may be mediated through uridine. The gene discussed is SLC5A2; the disease is prostate carcinoma.